InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Tuesday, 06/23/2020 2:29:46 PM

Tuesday, June 23, 2020 2:29:46 PM

Post# of 8169
7:44 am ET June 23, 2020
Cellectar Biosciences started at buy with $3 stock price target at Maxim Group

Maxim analyst Jason McCarthy initiated coverage of Cellectar Biosciences with a Buy rating and $3 price target. The analyst says the data in the company's development of phospholipid drug conjugates to target cancer's "addiction" to phospholipids have been "compelling". McCarthy further notes additional catalysts expected in the second half of 2020 and in 2021, with "updates on a pediatric study in solid tumors and r/r blood cancers", adding that Cellectar should also have cash runway well into 2021

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News